Business Context and Reporting Period
Filing identity: The submitted filing is a Form 10-Q for Selecta Biosciences, Inc., not Cartesian Therapeutics, Inc. It covers the quarter and six months ended June 30, 2021, and was filed August 12, 2021.
Selecta was a clinical-stage biopharmaceutical company developing its ImmTOR immune-tolerance platform for enzyme therapies, gene therapies and autoimmune diseases. It had no approved products or product sales; revenue was generated from collaborations and grants.
Key Financial Metrics
| Metric | Three months ended June 30, 2021 | Six months ended June 30, 2021 |
|---|---|---|
| Collaboration and grant revenue | $19.7 million | $30.7 million |
| Research and development expense | $14.5 million | $27.5 million |
| General and administrative expense | $4.7 million | $10.0 million |
| Operating income (loss) | $0.5 million | $(6.7) million |
| Net income (loss) | $4.6 million | $(20.0) million |
| Operating cash flow | Not separately presented | $(18.2) million |
| Net change in cash, cash equivalents and restricted cash | Not separately presented | $(12.9) million |
Revenue was concentrated in the Sobi license arrangement, including clinical-supply shipments and reimbursement of Phase 3 DISSOLVE program costs. Second-quarter operating margin was approximately 2.3%; six-month operating margin was approximately negative 21.8%. Second-quarter net margin was approximately 23.2%, while the six-month net margin was approximately negative 65.2%. The quarterly profit was substantially affected by a $4.8 million gain from remeasurement of warrant liabilities; the six-month period included an $11.9 million warrant-liability expense.
- Cash and cash equivalents: $125.7 million at June 30, 2021.
- Marketable securities: $24.4 million, consisting of corporate bonds and commercial paper.
- Cash, cash equivalents, restricted cash and marketable securities: $151.5 million.
- Accumulated deficit: $424.7 million.
- Term loan principal outstanding: $25.0 million; carrying value included $2.3 million current and $22.9 million long-term loan payable, net of discounts and deferred charges.
- Operating lease liabilities: $10.1 million.
- Warrant liabilities: $40.6 million, classified as Level 3 fair value liabilities.
- Stockholders’ deficit improved to $(4.2) million from $(18.0) million at December 31, 2020, primarily due to equity issuance and other paid-in-capital activity.
Material Changes Versus the Prior Comparable Period
- Second-quarter revenue increased from zero to $19.7 million, and six-month revenue increased from zero to $30.7 million, reflecting recognition under collaboration and grant arrangements entered into or active after the prior-year period.
- Second-quarter R&D expense increased 35% to $14.5 million, primarily because of consulting, salaries, and discovery and preclinical programs. Six-month R&D expense increased 8% to $27.5 million.
- Second-quarter G&A expense decreased 16% to $4.7 million; six-month G&A expense increased 2% to $10.0 million.
- Second-quarter results shifted from a $24.1 million net loss to $4.6 million of net income. The improvement was driven primarily by collaboration revenue and a favorable warrant-liability remeasurement.
- Six-month net loss improved from $43.7 million to $20.0 million, although warrant remeasurement produced an $11.9 million expense in 2021.
- Operating cash use declined to $18.2 million from $23.5 million. Financing cash flow increased to $30.3 million, primarily from $29.5 million of net at-the-market offering proceeds.
- The company purchased $24.4 million of marketable securities during the first six months of 2021, compared with no such purchases in the prior-year period.
- Common shares outstanding increased to 115.1 million from 108.1 million at year-end 2020, reflecting equity issuance and exercises.
Guidance, Outlook, Risks and Unusual Items
- Management stated that available cash, marketable securities and restricted cash were expected to fund operating expenses and capital requirements into the third quarter of 2023, although this estimate depended on assumptions that could prove incorrect.
- The company expected continuing operating losses and stated that substantial additional financing would be required. Potential sources included equity offerings, debt financing, strategic collaborations and grants.
- SEL-212 Phase 3 DISSOLVE I and II trials were underway for chronic refractory gout, with topline data expected in the second half of 2022. The program was funded by Sobi.
- AskBio opted out of development of the MMA indication in April 2021. Selecta intended to continue SEL-302 development independently and expected to file an IND in the third quarter of 2021.
- Topline results for the SEL-399 clinical trial were expected in the fourth quarter of 2021. IND filings for SEL-313 and the PBC program were expected in 2022.
- COVID-19 had not materially affected clinical programs as of the filing date, but management identified potential risks to trial enrollment, study execution, supply chains, manufacturing and access to capital.
- A stockholder derivative action and related demand letters concerned the December 2019 private placement. The litigation was stayed pending review by a board-appointed Special Committee; no liability was accrued because any potential liability was not estimable or probable.
- The company’s revenue was subject to significant timing variability and depended on collaboration performance, clinical progress, reimbursements and milestone achievement. No product revenue was expected for the foreseeable future.
Most Important Facts to Verify
- Confirm the issuer identity: the filing text identifies Selecta Biosciences, Inc. and ticker SELB, while the request metadata identifies Cartesian Therapeutics, Inc.
- Verify that the reported second-quarter profit was not indicative of recurring profitability, given the reliance on collaboration revenue and the $4.8 million warrant-liability gain.
- Review the assumptions supporting management’s cash-runway estimate through the third quarter of 2023 and the need for additional financing.
- Assess the timing, funding responsibilities and clinical risks of the Sobi-supported DISSOLVE trials and the planned SEL-302, SEL-399, SEL-313 and PBC programs.
- Monitor dilution and potential future obligations from the at-the-market program, outstanding options and approximately 12.4 million outstanding warrants.
- Review the $25.0 million term loan, its secured status, covenants, interest terms, repayment schedule and potential default-related acceleration.
- Follow the derivative litigation and Special Committee review relating to the 2019 private placement.